Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 605-611

  Pinguet, F ^a   Martel, P ^a   Fabbro, M ^a   Petit, I ^a   Canal, P ^b   Culine, S ^a   Astre, C ^a   Bressolle, F ^a,c,d  

^a Anticancer Center   (France)

^b Lab de Pharmacocinétique   (France)

^c Lab de Pharmacocinétique   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

Advanced malignancies; High dose melphalan; Peripheral blood hematopoietic progenitor cell transplantation; Pharmacokinetics

Indexed keywords

CHLORMETHINE DERIVATIVE; CREATININE; MELPHALAN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; ULTRAVIOLET RADIATION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; FEMALE; HALF-LIFE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS; OVARIAN NEOPLASMS; SARCOMA, EWING'S;

EID: 0031052291     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Samuels B, Bitran JD: High-dose intravenous melphalan: a review. J Clin Oncol 13: 1786-1799, 1995.
2. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD: The systemic administration of intravenous melphalan. J Clin Oncol 11: 1768-1782, 1988.
3. Taitersall MH, Jarman M, Newlands ES, Holyhead L, Milstead RAV, Weinberg A: Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14: 507-513, 1978.
4. Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T: Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharmacol 16: 300-305, 1986.
5. Gouyette A, Hartmann O, Pico JL: Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184-189, 1986.
6. Tranchand B, Ploin YD, Minuit MP, Sapet C, Biron P, Philip T, Ardiet C: High-dose melphalan dosage adjustment: possibility of using a test dose. Cancer Chemother Pharmacol 23: 95-100, 1989.
7. Ninane J, Baurain R, Selys A de, Trouet A, Cornu G: High dose melphalan in children with advanced malignant disease. Cancer Chemother Pharmacol 75: 263-267, 1985.
8. Bosanquet AG, Gilby ED: Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 355-362, 1982.
9. Taha AK, Ahmad RA, Rogers DW, Pritchard J, Rogers HJ: Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol 10: 212-216, 1983.
10. Hersh MR, Ludden TM, Kuhn JG, Kuight W: Pharmacokinetics of high-dose melphalan. Invest New Drugs 1: 331-334, 1983.
11. Cockcroft DW, Gault MH: Prediction of creatinine clearance from scrum creatinine. Nephron 16: 31-47, 1976.
12. Pinguet F, Martel P. Rouanet P, Fabbro M, Astre C: Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. Am J Hosp Pharm 51: 2701-2702, 1994.
13. Pinguet F, Joulia JM, Martel P, Grosse PY, Astre C, Bressolle F: High-performance liquid Chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. J Chromatogr 1996 in press
14. Gomeni C, Gomeni R, SIPHAR: An integrated computer system for statistical and pharmacokinetic data analysis. In: Serio A. O'Moore R, Tardini A, Roger FH, eds. Proceedings of the 7th International Congress of Medical Informatics. Europe 87, Rome: European Federation for Medical Informatics, September 1987, pp 507-516
15. Taburet AM, Steimer JL, Doucet D, Singlas E: Le temps de presence moyen dans l'organisme: un nouveau parametre pharmacocinetique. Therapie 41: 1-10, 1986.
16. Statgraphics Plus for Windows, Version 1.12, Copyright 1994, Statistical Graphics Corporation and Manugistics, Copyright 1994-1995. Rockville, Maryland, USA.
17. Recce PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, Sage RE: Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 22: 348-352, 1988.
18. Choi KE, Ratain MJ, Williams SF, Golick JA, Beschorner JC, Fullem LJ, Bitran JD: Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Cancer Res 49: 1318-1321, 1989.
19. Adair CG, Bridges JM, Desai ZR: Renal function in the elimination of oral melphalan in patients with multiple myeloma. Cancer Chemother Pharmacol 17: 185-188, 1986.
20. Zucchetti MD, Incalci M, Willems Y, Cavulli F, Sessa C: Lack of effect of cisplatin on iv L-PAM plasma pharmacokinetics in ovarian cancer patients. Cancer Chemother Pharmacol 22: 87-89, 1988.
21. Osterborg A, Ehrsson H, Eksborg S, Wallin I, Mellstedt H: Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur J Cancer Clin Oncol 25: 899-903, 1989.
22. Kergueris MF, Milpied N, Moreau P, Harousseau JL, Larousse C: Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res 14: 2379-2382, 1994.
23. Woodhouse KW, Hamilton P, Lennard A, Rawlins MD: The pharmacokinetics of melphalan in patients wth multiple myeloma. An intravenous/oral study using a conventional dose regimens. Eur J Clin Pharmacol 24: 283-285, 1983.
24. Smith DC, Jodrell DI, Egorin RM, Ambinder RM, Zuhowski EG, Kreis W, Ellis PG, Trump DL: Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Cancer Chemother Pharmacol 31: 363-368, 1993.
25. Lazarus HM, Herzig RH, Graham-Pole J: Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1: 359-367, 1983.
26. McElwain TJ, Hedley DW, Gordon MY, Jarman M, Millar JL, Pritchard J: High-dose melphalan and non-cryopreserved autologous hone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 7 (suppl 5): 360-371, 1979.
27. Davis TP, Peng YM, Goodman GC, Alberts DS: HPLC, MS and pharmacokinetics of melphalan, bisantrone an 13-cis-retinoic-acid. J Chromatogr 20: 511-514, 1982.